vs
Side-by-side financial comparison of Hologic (HOLX) and RANGE RESOURCES CORP (RRC). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $786.9M, roughly 1.3× RANGE RESOURCES CORP). RANGE RESOURCES CORP runs the higher net margin — 22.8% vs 17.1%, a 5.7% gap on every dollar of revenue. On growth, RANGE RESOURCES CORP posted the faster year-over-year revenue change (18.0% vs 2.5%). Over the past eight quarters, RANGE RESOURCES CORP's revenue compounded faster (14.6% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Range Resources Corporation is a natural gas exploration and production company, the headquartered is in Fort Worth, Texas. It operates in the Marcellus Formation, where it is the largest land owners.
HOLX vs RRC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $786.9M |
| Net Profit | $179.1M | $179.1M |
| Gross Margin | 56.0% | 94.5% |
| Operating Margin | 22.6% | — |
| Net Margin | 17.1% | 22.8% |
| Revenue YoY | 2.5% | 18.0% |
| Net Profit YoY | -10.9% | 88.8% |
| EPS (diluted) | $0.79 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $786.9M | ||
| Q3 25 | $1.0B | $655.3M | ||
| Q2 25 | $1.0B | $699.6M | ||
| Q1 25 | $1.0B | $846.3M | ||
| Q4 24 | $1.0B | $667.0M | ||
| Q3 24 | $988.0M | $567.9M | ||
| Q2 24 | $1.0B | $513.2M | ||
| Q1 24 | $1.0B | $598.8M |
| Q4 25 | $179.1M | $179.1M | ||
| Q3 25 | $187.2M | $144.3M | ||
| Q2 25 | $194.9M | $237.6M | ||
| Q1 25 | $-17.4M | $97.1M | ||
| Q4 24 | $201.0M | $94.8M | ||
| Q3 24 | $178.6M | $50.7M | ||
| Q2 24 | $194.5M | $28.7M | ||
| Q1 24 | $169.9M | $92.1M |
| Q4 25 | 56.0% | 94.5% | ||
| Q3 25 | 55.6% | 92.5% | ||
| Q2 25 | 56.3% | 95.0% | ||
| Q1 25 | 37.5% | 93.1% | ||
| Q4 24 | 56.8% | 93.7% | ||
| Q3 24 | 56.4% | 94.3% | ||
| Q2 24 | 55.4% | 93.4% | ||
| Q1 24 | 53.3% | 94.7% |
| Q4 25 | 22.6% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 24.9% | — | ||
| Q1 25 | -0.7% | — | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 23.3% | — | ||
| Q2 24 | 24.1% | — | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 17.1% | 22.8% | ||
| Q3 25 | 17.8% | 22.0% | ||
| Q2 25 | 19.0% | 34.0% | ||
| Q1 25 | -1.7% | 11.5% | ||
| Q4 24 | 19.7% | 14.2% | ||
| Q3 24 | 18.1% | 8.9% | ||
| Q2 24 | 19.2% | 5.6% | ||
| Q1 24 | 16.7% | 15.4% |
| Q4 25 | $0.79 | $0.75 | ||
| Q3 25 | $0.84 | $0.60 | ||
| Q2 25 | $0.86 | $0.99 | ||
| Q1 25 | $-0.08 | $0.40 | ||
| Q4 24 | $0.87 | $0.38 | ||
| Q3 24 | $0.75 | $0.21 | ||
| Q2 24 | $0.82 | $0.12 | ||
| Q1 24 | $0.72 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $204.0K |
| Total DebtLower is stronger | $2.5B | $1.2B |
| Stockholders' EquityBook value | $5.2B | $4.3B |
| Total Assets | $9.2B | $7.4B |
| Debt / EquityLower = less leverage | 0.48× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $204.0K | ||
| Q3 25 | $2.2B | $175.0K | ||
| Q2 25 | $1.9B | $134.0K | ||
| Q1 25 | $1.6B | $344.6M | ||
| Q4 24 | $2.0B | $304.5M | ||
| Q3 24 | $2.3B | $277.4M | ||
| Q2 24 | $2.4B | $251.1M | ||
| Q1 24 | $2.2B | $343.1M |
| Q4 25 | $2.5B | $1.2B | ||
| Q3 25 | $2.5B | $1.2B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.5B | $1.7B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $1.7B | ||
| Q2 24 | $2.5B | $1.7B | ||
| Q1 24 | $2.6B | $1.8B |
| Q4 25 | $5.2B | $4.3B | ||
| Q3 25 | $5.0B | $4.2B | ||
| Q2 25 | $4.8B | $4.1B | ||
| Q1 25 | $4.6B | $3.9B | ||
| Q4 24 | $4.8B | $3.9B | ||
| Q3 24 | $5.1B | $3.9B | ||
| Q2 24 | $5.0B | $3.9B | ||
| Q1 24 | $4.8B | $3.8B |
| Q4 25 | $9.2B | $7.4B | ||
| Q3 25 | $9.0B | $7.2B | ||
| Q2 25 | $8.8B | $7.1B | ||
| Q1 25 | $8.5B | $7.4B | ||
| Q4 24 | $8.7B | $7.3B | ||
| Q3 24 | $9.2B | $7.2B | ||
| Q2 24 | $8.9B | $7.3B | ||
| Q1 24 | $8.7B | $7.4B |
| Q4 25 | 0.48× | 0.28× | ||
| Q3 25 | 0.50× | 0.29× | ||
| Q2 25 | 0.52× | 0.29× | ||
| Q1 25 | 0.55× | 0.43× | ||
| Q4 24 | 0.53× | 0.43× | ||
| Q3 24 | 0.49× | 0.44× | ||
| Q2 24 | 0.51× | 0.44× | ||
| Q1 24 | 0.53× | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $257.5M |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $257.5M | ||
| Q3 25 | $355.1M | $247.5M | ||
| Q2 25 | $343.3M | $336.2M | ||
| Q1 25 | $169.4M | $330.1M | ||
| Q4 24 | $189.3M | $217.9M | ||
| Q3 24 | $367.0M | $245.9M | ||
| Q2 24 | $405.8M | $148.8M | ||
| Q1 24 | $292.4M | $331.9M |
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.28× | 1.44× | ||
| Q3 25 | 1.90× | 1.72× | ||
| Q2 25 | 1.76× | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | 0.94× | 2.30× | ||
| Q3 24 | 2.05× | 4.85× | ||
| Q2 24 | 2.09× | 5.18× | ||
| Q1 24 | 1.72× | 3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
